Meeting
2017 Genitourinary Cancers Symposium
Tumor genomic analysis for 128 renal cell carcinoma (RCC) patients receiving first-line everolimus: Correlation between outcome and mutations status in MTOR, TSC1, and TSC2.
Authors
Martin Henner Voss
Memorial Sloan Kettering Cancer Center, New York, NY
Martin Henner Voss , David Chen , Mahtab Marker , Jianing Xu , Parul Patel , Xia Han , James Hsieh , Robert J. Motzer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Penile, Urethral, and Testicular Cancers; Renal Cell Cancer
Track
Renal Cell Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT00903175
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 484)
DOI
10.1200/JCO.2017.35.6_suppl.484
Abstract #
484
Poster Bd #
E23
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Next-generation sequencing to reveal somatic mutations that confer sensitivity to everolimus.
First Author: Sun Min Lim
Poster
2015 ASCO Annual Meeting
Activating genomic mutations in the mTOR pathway predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a large multi-institutional cohort.
First Author: Andre Poisl Fay
First Author: Jie Lin
Poster
2017 ASCO Annual Meeting
Pathogenic variants in DNA damage response (DDR) genes in patients with advanced solid tumors.
First Author: Ecaterina Elena Ileana Dumbrava